Ningning Wang , Kexin Jiao , Jin He , Bochen Zhu , Nachuan Cheng , Jian Sun , Lan Chen , Wanjin Chen , Lingyun Gong , Kai Qiao , Jianying Xi , Qihan Wu , Chongbo Zhao , Wenhua Zhu
{"title":"Diagnosis of Challenging Spinal Muscular Atrophy Cases with Long-Read Sequencing","authors":"Ningning Wang , Kexin Jiao , Jin He , Bochen Zhu , Nachuan Cheng , Jian Sun , Lan Chen , Wanjin Chen , Lingyun Gong , Kai Qiao , Jianying Xi , Qihan Wu , Chongbo Zhao , Wenhua Zhu","doi":"10.1016/j.jmoldx.2024.02.004","DOIUrl":null,"url":null,"abstract":"<div><p>Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder primarily caused by the deletion or mutation of the survival motor neuron 1 (<em>SMN1</em>) gene. This study assesses the diagnostic potential of long-read sequencing (LRS) in three patients with SMA. For Patient 1, who has a heterozygous <em>SMN1</em> deletion, LRS unveiled a missense mutation in <em>SMN1</em> exon 5. In Patient 2, an <em>Alu/Alu</em>-mediated rearrangement covering the <em>SMN1</em> promoter and exon 1 was identified through a blend of multiplex ligation-dependent probe amplification, LRS, and PCR across the breakpoint. The third patient, born to a consanguineous family, bore four copies of hybrid <em>SMN</em> genes. LRS determined the genomic structures, indicating two distinct hybrids of <em>SMN2</em> exon 7 and <em>SMN1</em> exon 8. However, a discrepancy was found between the <em>SMN1</em>/<em>SMN2</em> ratio interpretations by LRS (0:2) and multiplex ligation-dependent probe amplification (0:4), which suggested a limitation of LRS in SMA diagnosis. In conclusion, this newly adapted long PCR–based third-generation sequencing introduces an additional avenue for SMA diagnosis.</p></div>","PeriodicalId":50128,"journal":{"name":"Journal of Molecular Diagnostics","volume":"26 5","pages":"Pages 364-373"},"PeriodicalIF":3.4000,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525157824000539","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder primarily caused by the deletion or mutation of the survival motor neuron 1 (SMN1) gene. This study assesses the diagnostic potential of long-read sequencing (LRS) in three patients with SMA. For Patient 1, who has a heterozygous SMN1 deletion, LRS unveiled a missense mutation in SMN1 exon 5. In Patient 2, an Alu/Alu-mediated rearrangement covering the SMN1 promoter and exon 1 was identified through a blend of multiplex ligation-dependent probe amplification, LRS, and PCR across the breakpoint. The third patient, born to a consanguineous family, bore four copies of hybrid SMN genes. LRS determined the genomic structures, indicating two distinct hybrids of SMN2 exon 7 and SMN1 exon 8. However, a discrepancy was found between the SMN1/SMN2 ratio interpretations by LRS (0:2) and multiplex ligation-dependent probe amplification (0:4), which suggested a limitation of LRS in SMA diagnosis. In conclusion, this newly adapted long PCR–based third-generation sequencing introduces an additional avenue for SMA diagnosis.
期刊介绍:
The Journal of Molecular Diagnostics, the official publication of the Association for Molecular Pathology (AMP), co-owned by the American Society for Investigative Pathology (ASIP), seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome for review articles that contain: novel discoveries or clinicopathologic correlations including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, clinical informatics, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods which may be applied to diagnosis or monitoring of disease or disease predisposition.